England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...
Eli Lilly LLY announced that the phase IV CHALLENGE-MIG study, evaluating the efficacy and safety of its migraine drug Emgality against Pfizer‘s PFE Nurtec ODT, failed to meet primary endpoint of ...
The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...
As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight directly to the oral drug with a head-to-head clinical trial. Eli ...
Eli Lilly secured federal approval for Emgality, the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks, the FDA announced June 4. 1.
Add Yahoo as a preferred source to see more of our stories on Google. Lilly Biotechnology Center is shown in San Diego after cutting price of insulin (Reuters) -Eli Lilly said on Friday its migraine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results